Scientific deep-dive
Endoscopic Sleeve vs Surgical Sleeve: Less Weight Lost, Fewer Complications
A systematic review found endoscopic sleeve gastroplasty produced 13.7-15.2% total body weight loss at six months against 23.5-23.6% for surgery, with complication rates of 2.0-2.7% against 9.2-16.9%.
Endoscopic sleeve gastroplasty stitches the stomach smaller through the mouth, with no incisions. Laparoscopic sleeve gastrectomy cuts part of it away. A systematic review comparing them found the endoscopic procedure produced 13.7–15.2% total body weight loss at six months against 23.5–23.6% for surgery — and complication rates of 2.0–2.7% against 9.2–16.9%.[1] Neither of those is the whole answer. Together they are the actual choice.
The two columns
| Endoscopic (ESG) | Surgical (LSG) | |
|---|---|---|
| Total body weight loss, 6 months | 13.7–15.2% | 23.5–23.6% |
| At 12 months | — | 29.3% (one study) |
| At 18 and 24 months | 14.8% and 18.6% | — |
| Complication rate | 2.0–2.7% | 9.2–16.9% |
| Grade IV or V complications | none | none |
Read the rows against each other rather than in isolation. Surgery produced roughly half again as much weight loss at six months. The endoscopic procedure produced roughly a quarter to a fifth as many complications. A person deciding between them is trading one for the other, and which trade is right depends on things a meta-analysis does not know about them.
The plateau
The review’s own conclusion contains a line that matters more than either headline figure: weight loss results for the endoscopic procedure appear to plateau after the one-year mark.[1] The 18- and 24-month figures — 14.8% and 18.6% — are consistent with that, sitting close to where six months already was.
If you are choosing a procedure on the strength of a six-month number, that is the sentence to weigh. A shallower curve that flattens early is a different long-term proposition from a steeper one, whatever the complication rates say.
Where the drugs sit in this
This comparison predates the current generation of weight-loss drugs being widely available, and neither procedure was compared against them here. That comparison is its own question, and we cover it separately: surgery versus GLP-1 drugs sets out how the two approaches compare on weight, and what the line drawn by surgery actually is covers the eligibility thresholds.
One thing worth knowing if you are considering either procedure: weight regain after bariatric surgery is common enough that GLP‑1 drugs are now used for it, which we cover in GLP-1s after bariatric surgery.
Frequently Asked Questions
References
- 1.Jalal MA, Cheng Q, Edye MB. Systematic Review and Meta-Analysis of Endoscopic Sleeve Gastroplasty with Comparison to Laparoscopic Sleeve Gastrectomy Obesity Surgery. 2020. PMID: 32304011.
Related research
Amycretin: A 24% Weight Figure, and the Trial It Came From
Once-weekly amycretin produced an estimated 24.3% bodyweight reduction at 36 weeks against 1.1% on placebo — from a single-site phase 1b/2a study of 125 people whose primary endpoint was counting adverse events.
5 min read
Another Molecule You Cannot Buy
A dual agonist reported 14.7% weight loss in thirteen weeks. The drug is approved nowhere, and a thirteen-week figure sits on the steepest part of a curve that flattens.
6 min read
Beyond the Scale: Blood Pressure, Lipids and What Else Changes
Pooling the individual records of 3,136 people, systolic blood pressure fell 4.95 mmHg further than placebo — and by about the same amount whether or not the person had hypertension.
7 min read
Bone Density on a GLP-1: The Trial That Compared It Against Exercise
A four-arm randomized trial found liraglutide alone lost hip and spine bone density relative to exercise — while the combination arm lost the most weight and held bone density level with placebo.
7 min read
Cancer Risk in People Without Diabetes
A study in obese adults without diabetes found 41% lower incidence of obesity-associated cancers. The median follow-up was two years — far too short to establish that a drug prevented anything.
6 min read
Compounded GLP-1s and the Adverse Event Reports
A FAERS study found more adverse event reports for compounded GLP-1s. Reports are voluntary and there is no denominator — but one finding survives that critique, and it is about arithmetic.
6 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Luvo Health
Moving between compounded and brand without changing seller
Pricing Compare
Get started →Strut Health
Semaglutide at $99/month, 48% under the register median
Pricing Compare
Get started →Pallas Health
Knowing which pharmacy fills the vial — it names Belmar Pharmacy
Pricing Compare
Get started →